Insider Selling: Liquidia (NASDAQ:LQDA) Director Sells $903,300.00 in Stock

Posted by Brenda Bartman on Jun 6th, 2026

Liquidia Corporation (NASDAQ:LQDA – Get Free Report) Director Arthur Kirsch sold 15,000 shares of the stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $60.22, for a total transaction of $903,300.00. Following the transaction, the director directly owned 15,000 shares in the company, valued at $903,300. The trade was a 50.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Liquidia Stock Performance

Shares of LQDA stock opened at $61.85 on Friday. The company has a debt-to-equity ratio of 1.18, a quick ratio of 2.03 and a current ratio of 2.22. Liquidia Corporation has a one year low of $11.85 and a one year high of $66.24. The company’s 50-day simple moving average is $46.78 and its 200-day simple moving average is $39.56. The stock has a market capitalization of $5.50 billion, a price-to-earnings ratio of 441.82 and a beta of 0.58.

Liquidia (NASDAQ:LQDA – Get Free Report) last issued its quarterly earnings results on Monday, May 11th. The company reported $0.52 EPS for the quarter, topping the consensus estimate of $0.41 by $0.11. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The business had revenue of $132.87 million for the quarter, compared to analysts’ expectations of $119.44 million. The business’s revenue was up 4187.1% compared to the same quarter last year. Equities analysts anticipate that Liquidia Corporation will post 2.97 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. Wall Street Zen raised shares of Liquidia from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 16th. Zacks Research raised shares of Liquidia from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 5th. Raymond James Financial reaffirmed a “strong-buy” rating and set a $68.00 price target on shares of Liquidia in a research report on Thursday. BTIG Research increased their price target on shares of Liquidia from $50.00 to $59.00 and gave the stock a “buy” rating in a research report on Monday, May 11th. Finally, HC Wainwright increased their price target on shares of Liquidia from $67.00 to $75.00 and gave the stock a “buy” rating in a research report on Friday. Three investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Liquidia currently has an average rating of “Moderate Buy” and an average target price of $55.63.

Read Our Latest Stock Analysis on LQDA

Institutional Trading of Liquidia

Hedge funds have recently made changes to their positions in the stock. Caprock Group LLC bought a new stake in shares of Liquidia in the 3rd quarter worth approximately $37,114,000. Apis Capital Advisors LLC bought a new stake in shares of Liquidia in the 3rd quarter worth approximately $9,569,000. Farallon Capital Management LLC lifted its holdings in shares of Liquidia by 102.1% in the 3rd quarter. Farallon Capital Management LLC now owns 8,565,638 shares of the company’s stock worth $194,783,000 after purchasing an additional 4,326,876 shares during the last quarter. GSA Capital Partners LLP lifted its holdings in shares of Liquidia by 63.6% in the 4th quarter. GSA Capital Partners LLP now owns 63,176 shares of the company’s stock worth $2,179,000 after purchasing an additional 24,555 shares during the last quarter. Finally, Tudor Investment Corp ET AL bought a new stake in shares of Liquidia in the 3rd quarter worth approximately $1,536,000. Institutional investors own 64.54% of the company’s stock.

About Liquidia

(Get Free Report)

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).